Jesús Fernández-Crespo: ”We will succeed when we align what we want to be with how we want to get it”
Organization and Strategy
Aortic aneurysm and fibrotic response Marfan syndrome Article reference:
UB-led study describes the cause of aortic stiffness in Marfan syndrome Read More »
ONCE collaborates in the project led by Ana Mendez Zunzunegui from the Cellular and molecular basis of sensory disorders research group at Bellvitge Biomedical Reseach Institute (IDIBELL) and professor at the University of Barcelona, which aims to identify new therapeutic targets against hereditary blindness. Hereditary retinal dystrophies are disorders with great clinical and genetic heterogeneity
ONCE and IDIBELL collaborating on a project on hereditary blindness Read More »
Robotic surgery is able to reduce the average hospital stay of highly complex procedures to 2.2 days The robotic surgical system with three-dimensional view provides greater accuracy and security both in laparoscopic surgery and oncology. The University Hospital of Bellvitge, with support from the Institute of Biomedical Research of Bellvitge (IDIBELL), has since 2009 of
Liquid biopsy Different mutations, different prognosis
A blood could replace lung cancer biopsies Read More »
Neuroscience at schools ‘Pessics’ with Brain Awareness Week
IDIBELL Neuroscientists in Brain Awareness Week Read More »
The head of the Infections and Cancer Lab at ICO-IDIBELL, Ignacio Gonzalez Bravo has received a Consolidator Grant from the European Research Council (ERC) to develop his CODOVIREVOL project: “Evolution of viral codon usage preferences: manipulation of translation accuracy and evasion of immune response “. The grant entails financing of 2 million euros for the
Ignacio Gonzalez Bravo awards a Consolidator Grant from the European Research Council Read More »
This year has been incorporated Francisco Miguel Torres in the IDIBELL as a new quality manager and responsible of scientific indicators of the institution. Francisco Miguel Torres graduated in Biology at the University of Barcelona and did a doctorate at the Vall d’Hebron Institute of Oncology (VHIO). He worked as a postdoctoral researcher at the